Clinical Trial: NCT03900598
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Janssen Research & Development, LLC |
| Information Provided By: | Janssen Research & Development, LLC |
| Last Update Posted: | 2025-06-22 |
Study Overview
Brief Summary
The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum tolerated dose of JNJ-67856633 in participants with relapsed/ refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Official Title
A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin
Intervention / Treatment
- Drug: JNJ-67856633
Other Study ID Numbers
- CR108587
- 67856633LYM1001
- 2018-003549-40
- 2024-512734-15-00
- 2018
Start Date (Actual)
2019-04-03
Primary Completion Date (Actual)
2025-05-22
Study Completion Date (Actual)
2025-05-22
Enrollment (Actual)
226
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Janssen Research & Development, LLC |
| Information Provided By: | Janssen Research & Development, LLC |
| Last Update Posted: | 2025-06-22 |
Study Overview
Brief Summary
The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum tolerated dose of JNJ-67856633 in participants with relapsed/ refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Official Title
A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin
Intervention / Treatment
- Drug: JNJ-67856633
Other Study ID Numbers
- CR108587
- 67856633LYM1001
- 2018-003549-40
- 2024-512734-15-00
- 2018
Start Date (Actual)
2019-04-03
Primary Completion Date (Actual)
2025-05-22
Study Completion Date (Actual)
2025-05-22
Enrollment (Actual)
226
Study Type
Interventional
Phase
Phase 1